Abstract:

Purpose: In this study oncology patients F18-florodeoxyglucose (FDG) positron emission tomography/computer tomography (PET/BT) COVID-19 vaccine-related hypermetabolic acceleration lymph nod incidence and hypermetabolic acceleration lymph nod influencing factors are aimed at mitigating. Patients and Method: From 15 January 2021 to 15 June 2021 patients with FDG PET/BT screening in our institution who were given one or two doses of COVID-19 vaccine (CoronaVac or Biontech) were included in the study. The presence and number of lymphatic nodes after the first and second vaccination was studied and there was no difference between the presence and number of lymphatic nodes, the presence of the FDG and these data. Results: in 9.9% of patients vaccinated with CoronaVac (18/182) [9.6% after dose 1 (9/94), 2. 10.2% after dose (9/88)]; in 37.5% of patients vaccinated with Biontech (9/24) [35% after dose 1 (7/20), 50% after dose 2 (2/4)] one-sided hypermetabolic axils were observed in the lymph nodes. In patients applied CoronaVac hypermetabolic acts with the presence of lymphatic nodes, a negative correlation between age and age was identified. The result: The hypertetabolic axils of the lymph nodus after CoronaVac were lower than observed and in the literature after the mRNA vaccines, which were a small group of patients in our study. However, the statistical difference was not assessed because the number of patients in the mRNA group was insufficient. It is recommended to take a short vaccination anamnesis before FDG PET/BT to reduce the negative positivities. The potential role of FDG PET/BT in comparing the effectiveness of vaccines produced by different biotechnologies should be studied by studies in wider patient populations.